Clinical Characteristics and Prognostic Analysis of Extramedullary Disease in Multiple Myeloma: A 15-Year Retrospective Cohort Study
Cancers · 03.08.2026 · 18 (15) · 2484
DOI: 10.3390/cancers18152484 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancers, online erschienen am 03.08.2026. Verfasst von Jingliang Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Hospital of Shanxi Medical University, 382 Wuyi Road, Taiyuan 030000, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Youth Project of National Natural Science Foundation of China, Shanxi Provincial Higher Education "Billion Project" Science and Technology Guidance Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Extramedullary disease (EMD) in multiple myeloma (MM) is associated with poor prognosis, yet the clinical distinctions between bone-related EMD (bEMD) and soft tissue-associated EMD (sEMD) remain incompletely characterized. This study aimed to compare the clinical features and outcomes of bEMD versus sEMD and to develop a simple pre-treatment risk stratification tool using baseline clinical parameters.
Methods
We retrospectively analyzed 118 patients with MM and EMD treated at a single center from 2011 to 2025, including 72 bEMD and 46 sEMD cases. Baseline characteristics, laboratory parameters, cytogenetic abnormalities, and survival outcomes were compared.
Results
Patients with sEMD had significantly higher serum β2-microglobulin (β2-MG) levels (6.4 mg/L vs. 4.5 mg/L, p = 0.007) and a higher proportion of relapsed/refractory disease (41.3% vs. 15.3%, p = 0.002) compared to bEMD. Median progression-free survival (PFS) and overall survival (OS) were markedly shorter in patients with sEMD than in those with bEMD (PFS: 12.0 vs. 29.0 months, p < 0.001; OS: 25.0 vs. 67.0 months, p = 0.009). Multivariate analysis identified thrombocytopenia (PLT < 100 × 109/L), elevated β2-MG, multisite extramedullary involvement, and TP53 deletion as independent adverse prognostic factors. A risk scoring system incorporating β2-MG (0–2 points), thrombocytopenia (1 point), and multisite involvement (1 point) stratified patients into low-risk (0–2 points) and high-risk (3–4 points) groups with significantly different PFS (27.0 vs. 10.0 months, p < 0.001) and OS (54.0 vs. 22.0 months, p = 0.008). Conclusions: sEMD represents a more aggressive subtype of MM with inferior outcomes. The proposed risk score, based on routinely available clinical parameters, effectively identifies high-risk patients at initial diagnosis and may guide individualized treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The Second Hospital of Shanxi Medical University, 382 Wuyi Road, Taiyuan 030000, China.
ORCID-Profile: Jingliang Zhao, Qirui Bai, Shengtao Li, Yanping Ma
Förderung
- Youth Project of National Natural Science Foundation of China
- Shanxi Provincial Higher Education "Billion Project" Science and Technology Guidance Project
- National Natural Science Foundation of China
- Shanxi Provincial Higher Education “Billion Project” Science and Technology Guidance Project
Zitieren
APA
Zhao, J., Bai, Q., Qiu, Q., Song, J., Kong, S., Zhu, K., Zhang, Y., Li, S., Ma, Y., Zhang, L., & Qin, X. (2026). Clinical Characteristics and Prognostic Analysis of Extramedullary Disease in Multiple Myeloma: A 15-Year Retrospective Cohort Study. Cancers, 18(15), 2484. https://doi.org/10.3390/cancers18152484
Vancouver
Zhao J, Bai Q, Qiu Q, Song J, Kong S, Zhu K, et al. Clinical Characteristics and Prognostic Analysis of Extramedullary Disease in Multiple Myeloma: A 15-Year Retrospective Cohort Study. Cancers. 2026;18(15):2484. doi:10.3390/cancers18152484
BibTeX
@article{Zhao2026,
author = {Zhao, Jingliang and Bai, Qirui and Qiu, Qile and Song, Jiaying and Kong, Siyu and Zhu, Kun and Zhang, Yifan and Li, Shengtao and Ma, Yanping and Zhang, Lin and Qin, Xiaoqi},
title = {Clinical Characteristics and Prognostic Analysis of Extramedullary Disease in Multiple Myeloma: A 15-Year Retrospective Cohort Study},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2484},
doi = {10.3390/cancers18152484}
}
EUVIMED